Literature DB >> 25096999

Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment.

Samuel J Klempner1, Golnaz Aubin2, Atreya Dash3, Sai-Hong Ignatius Ou1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25096999      PMCID: PMC4153456          DOI: 10.1634/theoncologist.2014-0216

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


× No keyword cloud information.
  8 in total

1.  Guidelines on the management of renal cyst disease.

Authors:  Thomas F Whelan
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

2.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

3.  The incidence of simple renal cyst by computed tomography.

Authors:  S Tada; J Yamagishi; H Kobayashi; Y Hata; T Kobari
Journal:  Clin Radiol       Date:  1983-07       Impact factor: 2.350

4.  The current radiological approach to renal cysts.

Authors:  M A Bosniak
Journal:  Radiology       Date:  1986-01       Impact factor: 11.105

Review 5.  Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.

Authors:  Sai-Hong Ignatius Ou; Cynthia Huang Bartlett; Mari Mino-Kenudson; Jean Cui; A John Iafrate
Journal:  Oncologist       Date:  2012-09-18

6.  Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

Authors:  S-H I Ou; P A Jänne; C H Bartlett; Y Tang; D-W Kim; G A Otterson; L Crinò; P Selaru; D P Cohen; J W Clark; G J Riely
Journal:  Ann Oncol       Date:  2014-02       Impact factor: 32.976

7.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

8.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316

  8 in total
  9 in total

Review 1.  Renal Toxicities of Targeted Therapies.

Authors:  Anum Abbas; Mohsin M Mirza; Apar Kishor Ganti; Ketki Tendulkar
Journal:  Target Oncol       Date:  2015-12       Impact factor: 4.493

2.  Crizotinib-induced pancreatic pseudocyst: a novel adverse event.

Authors:  Hiroo Ishida; Wataru Ichikawa; Yasutsuna Sasaki
Journal:  BMJ Case Rep       Date:  2015-09-08

3.  Imaging features of renal complications after crizotinib treatment for non-small-cell lung cancer: a case report.

Authors:  Wan Ying Chan; Mei-Kim Ang; Daniel Shao Weng Tan; Wan Lin Koh; Jin Wei Kwek
Journal:  Radiol Case Rep       Date:  2016-05-18

Review 4.  Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review.

Authors:  Kenar D Jhaveri; Rimda Wanchoo; Vipulbhai Sakhiya; Daniel W Ross; Steven Fishbane
Journal:  Kidney Int Rep       Date:  2016-09-21

5.  Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution.

Authors:  Laird B Cameron; Damian H S Jiang; Kate Moodie; Catherine Mitchell; Benjamin Solomon; Bimal Kumar Parameswaran
Journal:  Cancer Imaging       Date:  2017-02-16       Impact factor: 3.909

6.  Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib.

Authors:  Kageaki Taima; Hisashi Tanaka; Yoshihito Tanaka; Masamichi Itoga; Shingo Takanashi; Sadatomo Tasaka
Journal:  Intern Med       Date:  2017-08-10       Impact factor: 1.271

7.  Complex renal cysts associated with crizotinib treatment.

Authors:  Patrick Schnell; Cynthia H Bartlett; Benjamin J Solomon; Vanessa Tassell; Alice T Shaw; Tommaso de Pas; Soo-Hyun Lee; Geon Kook Lee; Kaoru Tanaka; Weiwei Tan; Yiyun Tang; Keith D Wilner; Allan Safferman; Ji-Youn Han
Journal:  Cancer Med       Date:  2015-03-10       Impact factor: 4.452

8.  Renal Injury during Long-Term Crizotinib Therapy.

Authors:  Taro Yasuma; Tetsu Kobayashi; Corina N D'Alessandro-Gabazza; Hajime Fujimoto; Kentaro Ito; Yoichi Nishii; Kota Nishihama; Prince Baffour Tonto; Atsuro Takeshita; Masaaki Toda; Esteban C Gabazza; Osamu Taguchi; Shigenori Yonemura; Osamu Hataji
Journal:  Int J Mol Sci       Date:  2018-09-25       Impact factor: 5.923

9.  Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib.

Authors:  Pietro Di Marino; Gianluca Mannetta; Consiglia Carella; Antonino Grassadonia; Nicola Tinari; Clara Natoli; Michele De Tursi
Journal:  Int Med Case Rep J       Date:  2020-03-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.